Aperio Group’s Albany Molecular Research Inc AMRI Stock Holding History

Aperio Group’s Portfolio AMRI Stock Details AMRI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-17,570	Closed	-$381K	–	2261
2017 Q2	$381K	Buy	17,570 +1,545	+10%	+$28K	﹤0.01%	1777
2017 Q1	$225K	Buy	16,025 +605	+4%	+$9.91K	﹤0.01%	1983
2016 Q4	$289K	Sell	15,420 -170	-1%	-$2.89K	﹤0.01%	1811
2016 Q3	$257K	Buy	15,590 +2,376	+18%	+$35.2K	﹤0.01%	1806
2016 Q2	$177K	Sell	13,214 -231	-2%	-$3.37K	﹤0.01%	1896
2016 Q1	$205K	Buy	+13,445	New	+$211K	﹤0.01%	1866

Other funds holding AMRI

Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Aperio Group's AMRI Position: Q3 2017 in Review

Aperio Group sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 17,570 shares — an estimated $381K sold.

Aperio Group first reported a position in AMRI in Q1 2016 and held it in 6 quarters. The position peaked at $381K in Q2 2017. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.

Aperio Group reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
Aperio Group sold 17,570 Albany Molecular Research Inc shares in Q3 2017, an estimated $381K.
Aperio Group first reported a position in Albany Molecular Research Inc in Q1 2016 and held it in 6 quarters.
Aperio Group's Albany Molecular Research Inc position peaked at $381K in Q2 2017.
2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.

Based on Aperio Group's 13F filing for Q3 2017, filed 25 Oct 2017.